Clinical Trials Logo

Biliary Tract Carcinoma clinical trials

View clinical trials related to Biliary Tract Carcinoma.

Filter by:

NCT ID: NCT06199882 Recruiting - Clinical trials for Biliary Tract Carcinoma

SBRT Sequential Surufatinib Combined With Immunotherapy for Biliary Tract Carcinoma

Start date: February 1, 2024
Phase: Phase 2
Study type: Interventional

This is a single-arm, open, single-center Phase II clinical study to observe and evaluate the efficacy and safety of SBRT sequential surufatinib combined with immunotherapy in patients with locally unresectable or recurrent biliary tract cancer after the first surgery.

NCT ID: NCT06168292 Not yet recruiting - Radiotherapy Clinical Trials

Intraductal Radiofrequency Thermoablation and Radiotherapy Combined Treatment for Extrahepatic Cholangiocarcinoma

Start date: December 10, 2023
Phase: N/A
Study type: Interventional

[Study objectives] To evaluate the efficacy and safety of the combined treatment of radiotherapy and endoscopic intraductal radiofrequency ablation in patients with locoregional extrahepatic cholangiocarcinoma.

NCT ID: NCT06048133 Recruiting - Cholangiocarcinoma Clinical Trials

Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)

Start date: March 8, 2024
Phase: Phase 2
Study type: Interventional

This is a phase 2 study of gemcitabine, cisplatin, zimberelimab (AB122) and quemliclustat (AB680) in subjects with untreated advanced biliary tract cancers (BTC). The study will include a safety run-in involving 6 study participants. The goal of the safety run-in is to screen for early safety signals of the proposed drug combination. Trial enrollment can continue while full safety assessment is being completed for the first 6 subjects. Participants will receive 4 cycles of combination therapy as described. After 4 cycles (~6 months), cisplatin will be discontinued, while gemcitabine, zimberelimab (AB122), and quemliclustat (AB680) will be continued. Subjects will be treated until disease progression or development of intolerable toxicities. In total, there will be up to 39 participants on the study.

NCT ID: NCT06047990 Recruiting - Biliary Obstruction Clinical Trials

Endobiliary Percutaneous Cryobiopsy in Malignant Biliary Obstruction

BICRYOB
Start date: June 1, 2023
Phase: N/A
Study type: Interventional

The rationale of the study is to explore the safety and efficacy of percutaneously performed endobiliary cryobiopsy in patiens with histologically unverified biliary stenosis.

NCT ID: NCT05845554 Recruiting - Clinical trials for Biliary Tract Carcinoma

Application of Chromosomal Instability in Early Diagnosis of Biliary Tract Carcinoma

Start date: March 30, 2023
Phase:
Study type: Observational

Chromosomal instability (CIN) refers to ongoing chromosome segregation errors throughout consecutive cell divisions. CIN is a hallmark of human cancer, and it is associated with poor prognosis, metastasis, and therapeutic resistance. Analyzing CIN of the DNA extracted from cast-off cells in bile samples seems a promising method for diagnosing, monitoring, and predicting the prognosis of biliary tract carcinoma patients. CIN can be assessed using experimental techniques such as bulk DNA sequencing, fluorescence in situ hybridization (FISH), or conventional karyotyping. However, these techniques are either time-consuming or non-specific. The investigators here intend to study whether a new method named Bile Ultrasensitive Chromosomal Aneuploidy Detection (BileCAD), which is based on low-coverage whole-genome sequencing, can be used to analyze CIN and microbial infection analysis thus help diagnosing and treating biliary tract carcinoma patients.

NCT ID: NCT05822453 Not yet recruiting - Clinical trials for Biliary Tract Carcinoma

Gemcitabine Plus S1 and Tislelizumab in the First Line Therapy of Advanced Biliary Tract Carcinoma

Start date: April 30, 2023
Phase: Phase 2
Study type: Interventional

This study will evaluate the efficacy and safety of 1st line therapy with gemcitabine plus S1 and tislelizumab in participants with advanced biliary tract carcinoma (BTC).

NCT ID: NCT05668884 Recruiting - Clinical trials for Biliary Tract Carcinoma

GEMOX Combined With Donafenib and Tislelizumab in Advanced Biliary Tract Carcinoma

Start date: October 18, 2022
Phase: Phase 2
Study type: Interventional

In this phase 2 study, the investigators aim to evaluate the effects and safety of combined therapy using oxaliplatin and gemcitabine chemotherapy, Donafenib and Tislelizumab for patients with advanced biliary tract carcinoma.

NCT ID: NCT05123482 Recruiting - Breast Cancer Clinical Trials

First in Human Study to Evaluate AZD8205 in Patients With Advanced or Metastatic Solid Malignancies

Start date: October 18, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This research study is studying a new compound, AZD8205, as a possible treatment for advanced or metastatic solid tumours

NCT ID: NCT05064852 Not yet recruiting - Clinical trials for Biliary Tract Carcinoma

A Real-world Study of the Safety and Efficacy of Surufatinib in the Treatment of Biliary Tract Carcinoma

Start date: September 20, 2021
Phase:
Study type: Observational

This is a prospective, single-arm, open-label,multi-center, observational real-world clinical study to observe and evaluate the efficacy and safety of Surufatinib in the treatment of patients with biliary tract cancer (BTC).

NCT ID: NCT05023109 Active, not recruiting - Clinical trials for Biliary Tract Carcinoma

GP Chemotherapy in Combination With Anti-PD-1 and Anti-TIGIT in Unresectable Advanced BTC

Start date: February 1, 2021
Phase: Phase 2
Study type: Interventional

This is an open label, multi-center, phaseâ…¡study to evaluate the efficacy and safety of GP (Gemcitabine/Cisplatin) in combination with Tislelizumab and Ociperlimab as first-line treatment in participants with unresectable advanced Biliary Tract Carcinoma (BTC).